Magee Colm C, Pascual Manuel
Renal Division, Brigham and Women's Hospital, Boston, MA 02115, USA.
Arch Intern Med. 2004 Jul 12;164(13):1373-88. doi: 10.1001/archinte.164.13.1373.
Renal transplantation is the treatment of choice for most patients with end-stage renal disease. The shortage of donor organs, however, remains a major obstacle to successful, early transplantation. This shortage has actually worsened despite an increase in living family-related and unrelated donors. On the other hand, over the last 10 years, allograft and recipient survival have significantly improved. This encouraging outcome reflects many factors, particularly a favorable shift in the balance between the efficacy and toxicity of immunosuppressive regimens. As acute rejection and early graft loss have become less common, the focus is increasingly directed toward the prevention and treatment of the long-term complications of renal transplantation. These include suboptimal allograft function, premature death, cardiovascular disease, and bone disease. Thus, a multidisciplinary approach--rather than management of immunological issues alone--is now required to optimize long-term outcomes of renal transplant recipients.
肾移植是大多数终末期肾病患者的首选治疗方法。然而,供体器官短缺仍然是成功进行早期移植的主要障碍。尽管活体亲属和非亲属供体有所增加,但这种短缺实际上却加剧了。另一方面,在过去10年中,同种异体移植和受者存活率有了显著提高。这一令人鼓舞的结果反映了许多因素,特别是免疫抑制方案的疗效和毒性之间的平衡发生了有利转变。随着急性排斥反应和早期移植物丢失变得不那么常见,重点越来越多地转向肾移植长期并发症的预防和治疗。这些并发症包括移植肾功能欠佳、过早死亡、心血管疾病和骨病。因此,现在需要一种多学科方法——而不是仅处理免疫问题——来优化肾移植受者的长期预后。